UIC
ABBV icon

Uniplan Investment Counsel’s AbbVie ABBV Stock Holding History

Uniplan Investment Counsel’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.65M Sell
16,800
-556
-3% -$123K 0.38% 71
2025
Q4 		$3.97M Buy
17,356
+486
+3% +$111K 0.4% 72
2025
Q3 		$3.91M Sell
16,870
-1,145
-6% -$233K 0.38% 68
2025
Q2 		$3.34M Sell
18,015
-10,080
-36% -$1.87M 0.34% 77
2025
Q1 		$5.89M Sell
28,095
-1,170
-4% -$227K 0.57% 48
2024
Q4 		$5.2M Sell
29,265
-21,174
-42% -$3.89M 0.48% 55
2024
Q3 		$9.96M Sell
50,439
-3,072
-6% -$573K 0.87% 30
2024
Q2 		$9.18M Sell
53,511
-954
-2% -$158K 0.83% 32
2024
Q1 		$9.92M Sell
54,465
-8,875
-14% -$1.53M 0.78% 34
2023
Q4 		$9.8M Sell
63,340
-4,462
-7% -$651K 0.73% 34
2023
Q3 		$9.13M Hold
67,802
– – 0.7% 41
2023
Q2 		$9.13M Sell
67,802
-1,551
-2% -$227K 0.66% 42
2023
Q1 		$11.1M Sell
69,353
-225
-0.3% -$34.4K 0.78% 35
2022
Q4 		$11.2M Buy
69,578
+5,699
+9% +$874K 0.8% 33
2022
Q3 		$8.57M Buy
63,879
+1,513
+2% +$217K 0.66% 39
2022
Q2 		$9.55M Buy
62,366
+4,807
+8% +$735K 0.67% 37
2022
Q1 		$9.33M Sell
57,559
-499
-0.9% -$72.5K 0.55% 41
2021
Q4 		$7.86M Sell
58,058
-2,498
-4% -$295K 0.44% 44
2021
Q3 		$6.53M Sell
60,556
-301
-0.5% -$34.4K 0.4% 50
2021
Q2 		$6.85M Sell
60,857
-4,076
-6% -$459K 0.4% 47
2021
Q1 		$7.03M Sell
64,933
-5,135
-7% -$549K 0.45% 47
2020
Q4 		$7.51M Sell
70,068
-8,942
-11% -$859K 0.51% 45
2020
Q3 		$6.92M Sell
79,010
-5,357
-6% -$504K 0.48% 46
2020
Q2 		$8.28M Sell
84,367
-11,271
-12% -$992K 0.58% 41
2020
Q1 		$7.29M Buy
95,638
+6,183
+7% +$527K 0.55% 43
2019
Q4 		$7.92M Sell
89,455
-5,991
-6% -$497K 0.47% 52
2019
Q3 		$7.23M Buy
+95,446
New +$6.54M 0.45% 50

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Uniplan Investment Counsel's ABBV Position: Q1 2026 in Review

Uniplan Investment Counsel reduced its AbbVie (ABBV) stake by 3.2% in Q1 2026, selling an estimated $123K and leaving 16,800 shares worth $3.65M. The position accounts for 0.38% of the portfolio, ranked #71.

Uniplan Investment Counsel first reported a position in ABBV in Q3 2019 and has held it in 27 quarters since. The position peaked at $11.2M in Q4 2022. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Uniplan Investment Counsel held 16,800 shares of AbbVie worth $3.65M as of Q1 2026.
  • Uniplan Investment Counsel sold 556 AbbVie shares in Q1 2026, an estimated $123K.
  • AbbVie made up 0.38% of Uniplan Investment Counsel's portfolio in Q1 2026, its #71 holding.
  • Uniplan Investment Counsel first reported a position in AbbVie in Q3 2019 and has held it in 27 quarters since.
  • Uniplan Investment Counsel's AbbVie position peaked at $11.2M in Q4 2022.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Uniplan Investment Counsel's 13F filing for Q1 2026, filed 15 May 2026.